Cancer treatment, especially at later stages, is a race against time, with many patients unable to access potentially life-saving therapies locked within the confines of clinical trials. Immunocine Cancer Center was founded by Dr. Matthew Halpert to change that narrative, offering advanced immunotherapy treatments to patients who otherwise wouldn't qualify for experimental protocols. At the heart of its groundbreaking approach is the Immunocine Dendritic Cell Treatment (IDCT), a method designed to leverage the body's natural immune system to target and destroy cancer cells while minimizing side effects.
Immunocine's IDCT protocol is the first to utilize a 'double loading' technique that equips dendritic cells with cancer-specific mRNA and antigens derived from a patient's tumor. This unique process simulates a viral infection, training the immune system to recognize and eliminate cancer cells throughout the body. Unlike traditional treatments like chemotherapy and radiation, which often harm healthy cells, Immunocine's approach is precise, attacking only the cancerous cells while preserving the body's overall health.
